Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality

Lisa K. Koch, Christoph Bucher, Angela Panoskaltsis-Mortari, Andrew L. Mellor, David H. Munn, Bruce R. Blazar

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

During graft-versus-host disease (GVHD), donor T cells become activated and migrate to tissue sites. Previously, we demonstrated a crucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation. Here, we show that upon arrival in the colon, activated donor T cells produced interferon-γ that up-regulated IDO, causing T-cell anergy and apoptosis. IDO induces GCN2 kinase, up-regulating a Tcell stress response implicated in IDO immunosuppression. Donor T cells did not require GCN2 kinase to respond to IDO, suggesting toxic IDO metabolites, and not tryptophan depletion, were responsible for suppression. When exogenous metabolites were administered, GVHD lethality was reduced. To determine whether IDO could be induced before transplantation for enhanced GVHD suppression, we first determined whether antigen-presenting cells (APCs) or epithelial cells were primarily responsible for IDO expression and subsequent GVHD suppression. Recipients with wild-type versus IDO-/- APCs had increased survival, regardless of epithelial-cell expression of IDO, suggesting that APCs were suitable targets for inducing IDO. Administration of an agonist to Toll-like receptor-7/8, a receptor expressed primarily on APCs, induced IDO and reduced injury in the colon and ameliorated lethality. We conclude that IDO up-regulation may have therapeutic potential for preventing GVHD in the clinic.

Original languageEnglish (US)
Pages (from-to)5062-5070
Number of pages9
JournalBlood
Volume114
Issue number24
DOIs
StatePublished - Dec 3 2009

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Graft vs Host Disease
Grafts
Tryptophan
T-cells
Antigen-Presenting Cells
T-Lymphocytes
Metabolites
Toll-Like Receptor 8
Colon
Phosphotransferases
Toll-Like Receptor 7
Epithelial Cells
Transplantation (surgical)
Poisons
Immunosuppressive Agents
Immunosuppression
Interferons

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. / Koch, Lisa K.; Bucher, Christoph; Panoskaltsis-Mortari, Angela; Mellor, Andrew L.; Munn, David H.; Blazar, Bruce R.

In: Blood, Vol. 114, No. 24, 03.12.2009, p. 5062-5070.

Research output: Contribution to journalArticle

Koch, Lisa K. ; Bucher, Christoph ; Panoskaltsis-Mortari, Angela ; Mellor, Andrew L. ; Munn, David H. ; Blazar, Bruce R. / Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. In: Blood. 2009 ; Vol. 114, No. 24. pp. 5062-5070.
@article{7246414fb08b4afcbac1bb2ecc371228,
title = "Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality",
abstract = "During graft-versus-host disease (GVHD), donor T cells become activated and migrate to tissue sites. Previously, we demonstrated a crucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation. Here, we show that upon arrival in the colon, activated donor T cells produced interferon-γ that up-regulated IDO, causing T-cell anergy and apoptosis. IDO induces GCN2 kinase, up-regulating a Tcell stress response implicated in IDO immunosuppression. Donor T cells did not require GCN2 kinase to respond to IDO, suggesting toxic IDO metabolites, and not tryptophan depletion, were responsible for suppression. When exogenous metabolites were administered, GVHD lethality was reduced. To determine whether IDO could be induced before transplantation for enhanced GVHD suppression, we first determined whether antigen-presenting cells (APCs) or epithelial cells were primarily responsible for IDO expression and subsequent GVHD suppression. Recipients with wild-type versus IDO-/- APCs had increased survival, regardless of epithelial-cell expression of IDO, suggesting that APCs were suitable targets for inducing IDO. Administration of an agonist to Toll-like receptor-7/8, a receptor expressed primarily on APCs, induced IDO and reduced injury in the colon and ameliorated lethality. We conclude that IDO up-regulation may have therapeutic potential for preventing GVHD in the clinic.",
author = "Koch, {Lisa K.} and Christoph Bucher and Angela Panoskaltsis-Mortari and Mellor, {Andrew L.} and Munn, {David H.} and Blazar, {Bruce R.}",
year = "2009",
month = "12",
day = "3",
doi = "10.1182/blood-2009-06-227587",
language = "English (US)",
volume = "114",
pages = "5062--5070",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality

AU - Koch, Lisa K.

AU - Bucher, Christoph

AU - Panoskaltsis-Mortari, Angela

AU - Mellor, Andrew L.

AU - Munn, David H.

AU - Blazar, Bruce R.

PY - 2009/12/3

Y1 - 2009/12/3

N2 - During graft-versus-host disease (GVHD), donor T cells become activated and migrate to tissue sites. Previously, we demonstrated a crucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation. Here, we show that upon arrival in the colon, activated donor T cells produced interferon-γ that up-regulated IDO, causing T-cell anergy and apoptosis. IDO induces GCN2 kinase, up-regulating a Tcell stress response implicated in IDO immunosuppression. Donor T cells did not require GCN2 kinase to respond to IDO, suggesting toxic IDO metabolites, and not tryptophan depletion, were responsible for suppression. When exogenous metabolites were administered, GVHD lethality was reduced. To determine whether IDO could be induced before transplantation for enhanced GVHD suppression, we first determined whether antigen-presenting cells (APCs) or epithelial cells were primarily responsible for IDO expression and subsequent GVHD suppression. Recipients with wild-type versus IDO-/- APCs had increased survival, regardless of epithelial-cell expression of IDO, suggesting that APCs were suitable targets for inducing IDO. Administration of an agonist to Toll-like receptor-7/8, a receptor expressed primarily on APCs, induced IDO and reduced injury in the colon and ameliorated lethality. We conclude that IDO up-regulation may have therapeutic potential for preventing GVHD in the clinic.

AB - During graft-versus-host disease (GVHD), donor T cells become activated and migrate to tissue sites. Previously, we demonstrated a crucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation. Here, we show that upon arrival in the colon, activated donor T cells produced interferon-γ that up-regulated IDO, causing T-cell anergy and apoptosis. IDO induces GCN2 kinase, up-regulating a Tcell stress response implicated in IDO immunosuppression. Donor T cells did not require GCN2 kinase to respond to IDO, suggesting toxic IDO metabolites, and not tryptophan depletion, were responsible for suppression. When exogenous metabolites were administered, GVHD lethality was reduced. To determine whether IDO could be induced before transplantation for enhanced GVHD suppression, we first determined whether antigen-presenting cells (APCs) or epithelial cells were primarily responsible for IDO expression and subsequent GVHD suppression. Recipients with wild-type versus IDO-/- APCs had increased survival, regardless of epithelial-cell expression of IDO, suggesting that APCs were suitable targets for inducing IDO. Administration of an agonist to Toll-like receptor-7/8, a receptor expressed primarily on APCs, induced IDO and reduced injury in the colon and ameliorated lethality. We conclude that IDO up-regulation may have therapeutic potential for preventing GVHD in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=73949103808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949103808&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-06-227587

DO - 10.1182/blood-2009-06-227587

M3 - Article

C2 - 19828695

AN - SCOPUS:73949103808

VL - 114

SP - 5062

EP - 5070

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -